COVID-19: Identification and Development of Clinical Candidates to Treat SARS-CoV-2

COVID-19：识别和开发治疗 SARS-CoV-2 的临床候选药物

• 批准号: 10259371
• 负责人: Donald Lo
• 金额: $ 199.15万
• 依托单位: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10259371
• 关键词: 2019-nCoV; Address; Advanced Development; Ambulatory Care; Antiviral Agents; Automobile Driving; Autophagocytosis; Binding; Biological; Biological Assay; Biological Availability; COVID-19; COVID-19 pandemic; Cell Surface Receptors; Cells; Chemistry; Clinical; Clinical Investigator; Clinical Trials; Collaborations; Collection; Communities; Coronavirus; DNA-Directed RNA Polymerase; Data; Data Set; Development; Disease; Drug Combinations; Drug usage; Ebola virus; Emergency Situation; Enzymes; Fluorescence Resonance Energy Transfer; Formulation; Genome; Genomics; Glycoproteins; HIV; Hepatitis C virus; Host Defense Mechanism; Human; In Vitro; Infection; Influenza; Intravenous infusion procedures; Investigation; Investigational Drugs; Investigational New Drug Application; Joints; Laboratories; Lead; Libraries; Luciferases; Mannose; Measures; Mediating; Middle East Respiratory Syndrome; Middle East Respiratory Syndrome Coronavirus; Names; Natural Products; Nucleocapsid Proteins; Oligosaccharides; Patients; Peptide Hydrolases; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacology; Plasmids; Play; Positioning Attribute; Process; Production; Proteins; Protocols documentation; Public Health; RNA; RNA Polymerase Inhibitor; RNA-Directed RNA Polymerase; Replicon; Reporter; Reporter Genes; Research; Research Activity; Research Institute; Research Personnel; Research Support; Resources; Role; SARS coronavirus; Safety; Scientist; Severe Acute Respiratory Syndrome; Signal Transduction; Societies; System; Testing; Therapeutic Intervention; Time; Toxicology; Training; Transfection; Translational Research; United States National Institutes of Health; Universities; Vaccines; Viral; Viral Antigens; Viral Packaging; Virus; Virus Replication; Work; atypical pneumonia; base; biosafety level 3 facility; clinical candidate; clinical development; clinical efficacy; clinical investigation; coronavirus disease; data portal; drug candidate; drug development; drug discovery; experience; in vivo; inhibitor/antagonist; microbicide; model development; novel; novel therapeutics; open data; operation; pandemic disease; particle; pathogen; pharmacokinetics and pharmacodynamics; phase I trial; pre-clinical; remdesivir; research clinical testing; sharing platform; small molecule; therapeutic candidate; therapeutic development; viral RNA; virtual model

TDB scientists have extensive experience in developing novel therapeutic candidates as well as repurposing existing treatments for novel therapeutic purposes. Drug repurposing seeks to explore new uses for existing drugs and therapeutic candidates that already possess detailed pharmacology, formulation, and safety data, which can reduce the time to reach clinical testing for the new indication. TDB rapidly initiated several repurposing campaigns to identify modulators of SARS-CoV-2 activity. Targets under investigation include host defense mechanisms, such as cellular autophagy, and viral entry into cells through interaction of the viral spike protein with human cell surface receptors. TDB scientists also are contributing assay data and protocols to the Open Data Portal, a resource created by NCATS to house a collection of datasets generated from SARS-CoV-2-related assays against all approved drugs in the NCATS Pharmaceutical Collection. This effort aims to share COVID-19 related data in an open data-sharing platform to allow research scientists, clinical investigators and public health officials to prioritize promising compounds and repurposed drugs for further development in treating COVID-19. We have worked in collaboration with experts in and outside of NIH on the development of 8 assays for use in repurposing screens of approved drug collections to identify compounds active against SARS-CoV-2. The compounds identified from such screens have potential for clinical trials as single agents or in drug combinations to treat COVID-19 patients. 1. A SARS-CoV-2 pseudotyped particle (PP) entry assay in collaboration with Gary Whittaker (Cornell University). The PPs were generated with three plasmid transfection system containing MLV gag-pol, CoV spike, and luciferase reporter gene w/ viral packaging signal. In the assay process, the PPs deliver luciferase reporter RNA to host cells via spike-mediated cell entry. This assay has been used for screen the inhibitors of SARS-CoV-2 entry as well as the mechanistic study of other compounds identified from other assays. 2. SARS pseudotyped particle (PP) entry assay and MERS entry assays in collaboration with Gary Whittaker (Cornell University). Both assays have been optimized for 1536-well screens and used for drug repurposing screens of approved drug collection. The identified hits were further evaluated in a cytopathic effect assay with live SARS-CoV-2 infection (Southern Research Institute) to identify anti-SARS-CoV2 compounds that have broad activity against coronaviruses. 3. A SARS-CoV-2 cytopathic effect assay in Vero 6 cells in collaboration with the Southern Research Institute (SRI). Several small collections of approximately 10,000 approved and investigational drugs, preclinical drug candidates, and bioactive compounds were screened using assay ready plates, prepared by NCATS, in the BSL-3 lab at SRI. This assay has also been used to evaluate anti-SARS-CoV-2 compounds identified from NCATSs BSL-2 assays. 4. A SARS-CoV-2 3CL protease (also named main protease) assay. This viral protease plays a critical role in SARS-CoV-2 viral replication. We have developed and optimized this enzyme assay and screened a collection of approximately 10,000 compounds. Currently, a virtual modeling screen of the entire NCATS compound collection is in progress using the data from this focused library screen as a training set. The lead compounds will be used for chemistry optimization for further drug development. 5. A SARS-CoV-2 RNA dependent RNA polymerase (RdRP) assay. This viral RNA polymerase is critical to SARS-CoV-2 viral replication in host cells. Remdesivir, an RdRP inhibitor originally developed for Ebola virus and other viruses, has been authorized by the FDA for emergency use in hospitalized COVID-19 patients. The efficacy and potency of this drug are limited for SARS-CoV-2, as it was not originally developed for this virus. Remdesivir is currently only administered by intravenous infusion that precludes it from outpatient treatment. We are developing a SARS-CoV-2 RdRP enzyme assay and a cell-based RdRP assay to support repurposing screens for new drug development. 6. A SARS-CoV-2 replicon assay for use BSL-2 laboratories. Research involving live SARS-CoV-2 virus requires BSL-3 facility, which greatly limits throughput. We are collaborating with three laboratories to develop a replicon type assay for SARS-CoV-2, similar to our previous work on HCV. This replicon assay will have a SARS-CoV-2 genomic fragment encompassing viral replication machinery, without the viral envelop proteins, and will include a mini-genome reporter gene (luciferase). We will use this assay to screen NCATS compound collections for drug discovery and development. 7. An AlphaLISA assay to detect the SARS-CoV-2 Nucleocapsid (N) protein. Currently, the cytopathic effect (CPE) assay of SARS-CoV-2 allows for the greatest throughput in BSL-3 laboratories, but uses a surrogate readout for host cell infection (cell death). The AlphaLISA N protein assay would allow BSL-3 labs to directly measure viral antigen production upon SARS-CoV-2 infection in host cells. This assay is homogenous and amenable to HTS. It was developed to help increase the throughput of BSL3 labs. 8. A TR-FRET (HTRF) assay to detect the SARS-CoV-2 Nucleocapsid (N) protein. This assay is similar to the AlphaLISA N protein assay, but uses a different readout. This assay could be used as an alternative assay for HTS, or as an orthogonal assay to confirm the hits identified from the above AlphaLISA assay. We also have begun a partnership to rapidly progress a candidate into clinical trials for SARS-CoV-2. Our collaborators recently completed phase I trials of a protein natural product for use as a microbicide against HIV. Its mechanism of action, selectively binding to high-mannose oligosaccharides on viral envelope glycoproteins, is relevant to diverse pathogens, including HIV, Influenza, Ebolavirus, and SARS-CoV. The candidate has shown in vitro and in vivo activity against several coronaviruses, including SARS-CoV and MERS-CoV. Because it binds the spike glycoprotein on SARS-CoV, it is likely to have activity against all coronavirus strains, not only the SARS-CoV-2 driving the current COVID-19 pandemic.